Impact of Minimal Extrathyroidal Extension on Recurrence in Papillary Thyroid Carcinoma Measuring 4 cm or Less without Clinical Lymph Node Metastasis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: American Thyroid Association's guidelines (2015) recommend that papillary thyroid carcinomas (PTCs) ≤4 cm without extrathyroidal extension (ETE) and clinical lymph node metastasis (cLNM) can be treated by a unilateral procedure if a slightly higher risk of locoregional recurrence is accepted. The aim of the present study is to evaluate impact of minimal ETE (mETE) on locoregional recurrence in PTCs ≤4 cm without cLNM. Methods: The medical records of patients who underwent thyroidectomy for PTC ≤4 cm between January 1, 2007 and December 31, 2013 were retrospectively reviewed. Patients who had PTC with gross ETE and/or cLNM were excluded.-Patients with papillary thyroid microcarcinoma (PTMC) without ETE (group I; n=381) were compared with three other groups of patients: PTC 1–4 cm without ETE (group II; n=150); PTC ≤1 cm with mETE (group III; n=186); and PTC 1–4 cm with mETE (group IV; n=121). Mean follow-up period was 72.2±26.4 months. Results: Multiplicity, bilaterality, LNM, and total thyroidectomy were more common in group III and IV. Five-year disease-free survival (DFS) was 100%, 97.9%, 95.9%, and 94.9% in group I, II, III, and IV, respectively. DFS rates were significantly higher in group I compared to the other groups (P<0.01). There were no significant differences among group II, III, and IV. Conclusion: Compared to PTMC without ETE, mETE in PTC ≤4 cm without cLNM may be associated with more aggressive biological behavior and increased risk of recurrence, although the increments may be relatively small.
Abstract
Purpose: American Thyroid Association's guidelines (2015) recommend that papillary thyroid carcinomas (PTCs) ≤4 cm without extrathyroidal extension (ETE) and clinical lymph node metastasis (cLNM) can be treated by a unilateral procedure if a slightly higher risk of locoregional recurrence is accepted. The aim of the present study is to evaluate impact of minimal ETE (mETE) on locoregional recurrence in PTCs ≤4 cm without cLNM. Methods: The medical records of patients who underwent thyroidectomy for PTC ≤4 cm between January 1, 2007 and December 31, 2013 were retrospectively reviewed. Patients who had PTC with gross ETE and/or cLNM were excluded.-Patients with papillary thyroid microcarcinoma (PTMC) without ETE (group I; n=381) were compared with three other groups of patients: PTC 1–4 cm without ETE (group II; n=150); PTC ≤1 cm with mETE (group III; n=186); and PTC 1–4 cm with mETE (group IV; n=121). Mean follow-up period was 72.2±26.4 months. Results: Multiplicity, bilaterality, LNM, and total thyroidectomy were more common in group III and IV. Five-year disease-free survival (DFS) was 100%, 97.9%, 95.9%, and 94.9% in group I, II, III, and IV, respectively. DFS rates were significantly higher in group I compared to the other groups (P<0.01). There were no significant differences among group II, III, and IV. Conclusion: Compared to PTMC without ETE, mETE in PTC ≤4 cm without cLNM may be associated with more aggressive biological behavior and increased risk of recurrence, although the increments may be relatively small.
참고문헌 (10)
- American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19, pp.1167~1214 (2009)
- Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer", Thyroid, 26, pp.1~133 (2016)
- Amin MB, "American Joint Committee on Cancer. AJCC Cancer Staging Manual" (2017), Springer
- Bilimoria KY, "Extent of surgery affects survival for papillary thyroid cancer", Ann Surg, 246, pp.375~381 (2007)
- Mendelsohn AH, "Surgery for papillary thyroid carcinoma: is lobectomy enough?", Arch Otolaryngol Head Neck Surg, 136, pp.1055~1061 (2010)
- Barney BM, "Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer", Head Neck, 33, pp.645~649 (2011)
- Adam MA, "Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients", Ann Surg, 260, pp.601~605 (2014)
- Sosa JA, "The importance of surgeon experience for clinical and economic outcomes from thyroidectomy", Ann Surg, 228, pp.320~330 (1998)
- Randolph GW, "The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension", Thyroid, 22, pp.1144~1152 (2012)
- Ito Y, "Prognosis of low-risk papillary thyroid carcinoma patients : its relationship with the size of primary tumors", Endocr J, 59, pp.119~125 (2012)